Questcor Pharmaceuticals Inc (QCOR)

93.60
1.52 1.65
NASDAQ : Health Care
Prev Close 92.08
Open 92.93
Day Low/High 92.17 / 94.42
52 Wk Low/High 47.71 / 97.80
Volume 3.18M
Avg Volume 1.57M
Exchange NASDAQ
Shares Outstanding 61.45M
Market Cap 5.75B
EPS 4.99
P/E Ratio 16.10
Div & Yield 1.20 (1.30%)

Latest News

Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals

Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals

- Creates a diversified, high-growth therapeutic portfolio, capable of delivering substantial, sustainable value for shareholders

Retrophin CEO Under Fire for Twitter Faux Pas

Retrophin CEO Under Fire for Twitter Faux Pas

Retropin employees were using alias Twitter accounts -- two of which affected the persona of gangster rappers -- to promote Retrophin and pitch short-sale recommendations of other stocks to followers.

Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction

Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction

--Registration Statement on Form S-4 Declared Effective by SEC--

Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today

Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today

Trade-Ideas LLC identified Questcor Pharmaceuticals (QCOR) as a new lifetime high candidate

Trade-Ideas: Questcor Pharmaceuticals (QCOR) Is Today's Post-Market Leader Stock

Trade-Ideas: Questcor Pharmaceuticals (QCOR) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Questcor Pharmaceuticals (QCOR) as a post-market leader candidate

Questcor Pharmaceuticals Closes Transaction To Acquire International Rights To Synacthen® And Synacthen® Depot

Questcor Pharmaceuticals Closes Transaction To Acquire International Rights To Synacthen® And Synacthen® Depot

- Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects -

Why a 5% to 10% market correction may be in the cards

Why a 5% to 10% market correction may be in the cards

Mid-term election years historically are bumpy ones for stocks.

Today's Post-Market Laggard: Questcor Pharmaceuticals (QCOR)

Today's Post-Market Laggard: Questcor Pharmaceuticals (QCOR)

Trade-Ideas LLC identified Questcor Pharmaceuticals (QCOR) as a post-market laggard candidate

Questcor Provides Support To Lupus Foundation Of America Awareness, Education And Advocacy Efforts

Questcor Provides Support To Lupus Foundation Of America Awareness, Education And Advocacy Efforts

Company sponsors Walk to End Lupus Nowa¿¢ events and employees show support for people with the disease during Lupus Awareness Month

Today's Stocks Driving Success For The Health Care Sector

Today's Stocks Driving Success For The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector higher today.

Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides

Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides

- Expands pipeline and broadens platform with next-generation melanocortin peptides -

Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Announce Early Termination Of HSR Act Waiting Period

Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Announce Early Termination Of HSR Act Waiting Period

Mallinckrodt plc (NYSE: MNK), and Questcor Pharmaceuticals, Inc.

New Lifetime High Today: Questcor Pharmaceuticals (QCOR)

New Lifetime High Today: Questcor Pharmaceuticals (QCOR)

Trade-Ideas LLC identified Questcor Pharmaceuticals (QCOR) as a new lifetime high candidate

Questcor Pharmaceuticals Inc (QCOR): Today's Featured Drugs Winner

Questcor Pharmaceuticals Inc (QCOR): Today's Featured Drugs Winner

Questcor Pharmaceuticals was a winner within the drugs industry, rising $1.09 (1.3%) to $84.24 on light volume

Clinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity In Patients With Systemic Lupus Erythematosus

Clinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity In Patients With Systemic Lupus Erythematosus

- Significant clinical response to Acthar was observed in patients experiencing active disease while on conventional SLE maintenance therapies -

Questcor CEO's Daughter Granted Huge Pay Raise

Questcor CEO's Daughter Granted Huge Pay Raise

Her salary jumps to more than $1 million in 2013 from $300,000 in 2012, according to Questcor disclosure.

INVESTOR ALERT – Questcor Pharmaceuticals, Inc.: The Law Offices Of Vincent Wong Investigates The Sale Of Questcor Pharmaceuticals, Inc. To Mallinckrodt

INVESTOR ALERT – Questcor Pharmaceuticals, Inc.: The Law Offices Of Vincent Wong Investigates The Sale Of Questcor Pharmaceuticals, Inc. To Mallinckrodt

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Questcor Pharmaceuticals Inc.

Questcor Pharmaceuticals Inc (QCOR): Today's Featured Drugs Laggard

Questcor Pharmaceuticals Inc (QCOR): Today's Featured Drugs Laggard

Questcor Pharmaceuticals was a leading decliner within the drugs industry, falling $2.45 (-3.0%) to $79.05 on average volume

Clinical Trial Results Indicate Acthar May Significantly Reduce Proteinuria In Patients With Nephrotic Syndrome Due To Idiopathic Membranous Nephropathy

Clinical Trial Results Indicate Acthar May Significantly Reduce Proteinuria In Patients With Nephrotic Syndrome Due To Idiopathic Membranous Nephropathy

- Clinical results appear to correlate with reduction in anti-PLA2R antibodies

Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Laggard

Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Laggard

Questcor Pharmaceuticals was a leading decliner within the drugs industry, falling $1.51 (-1.9%) to $76.95 on light volume

QUESTCOR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Questcor Pharmaceuticals Inc. Over The Proposed Sale Of The Company To Mallinckrodt Plc

QUESTCOR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Questcor Pharmaceuticals Inc. Over The Proposed Sale Of The Company To Mallinckrodt Plc

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Questcor Pharmaceuticals Inc.